Prostate cancer
Conditions
Interventions
High dose rate brachytherapy (27 Gy / 2 fractions) Androgen deprivation therapy according to risk classification.
Sponsors
National Cancer Center Hospital, Japan. Department of Radiation Oncology.
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Pathologically diagnosed prostate adenocarcinoma. 2) T1c-3bN0M0 3) PSA value under 50 ng/ml 4) Gleason score 6-10 5) Low, intermediate, high and very high risk (NCCN risk classification 2016) 6) Age :20-80 7) Performance status (ECOG) 0-1 8) Written informed consent 9) Patient chooses this trial method.
Exclusion criteria
Exclusion criteria: 1) Other cancers 2) Uncontrolled Diabetes Mellitus 3) Severe comobidity such as collagen disease, heart disease, respiratory disease and liver disease. 4) Patient with severe psychiatric disease. 5) Privious medical history of pelvic irradiation. 6) Privious medical history of surgery or HIFU for prostate cancer. 7) Chemotherapy (except androgen deprivation therapy) for prostate cancer. 8) Inflammatory bowel disease 9) IPSS score more than or equal to 22. 10) Difficult to protect dose constraints for normal tissue. 11) Attending physician judges it is not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The occurence of more than or equal to Grade 3 late adverse effects in two years. 2. 5 year PSA relapse free rate. | — |
Countries
Japan
Contacts
Public ContactKoji Inaba
National Cancer Center Hospital, Japan. Department of Radiation Oncology
Outcome results
None listed